glp-1 substance abuse receptor agonists show promise in treating use disorders Substance use disorders (SUDs) may
Description
Commun Med
This narrative review summarises the role of incretin mimetics, individually or in combination therapy, in the treatment of MASLD/MASHhighlighting the pathophysiology and mechanisms of action, recent evidence from phase 2 and 3 MASH clinical trials, and clinical benefits
Roos, A
This persistent chatter includes thoughts about when to eat next, what to eat, and feelings of guilt or anxiety surrounding meals
We used a fresh aliquot for each experiment
What is NAION
